Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. With the development of the CyberKnife^® Robotic Radiosurgery System, Accuray revolutionized the field of radiosurgery, which was once confined to neurosurgical indications. The CyberKnife System can be used to treat tumors anywhere in the bodyincluding spine, lung, prostate, liver and pancreas. Today, theseextracranial treatments represent more than 50 percent of CyberKnife procedures and are some of the fastest growing applications, offering new options and new hope for many patients.

The CyberKnife System is the first and only commercially available radiosurgery system to combine image guidance and robotic mobility. These two elements enable the CyberKnife System to treat tumors from literally hundreds of angles throughout the body, enabling treatment with pinpoint precision and minimizing damage to surrounding healthy tissue.

Since the launch of the CyberKnife System, Accuray has undertaken a development strategy to allow clinicians to non-invasively treat tumors anywhere in the body with the highest levels of accuracy, in order to improve patient care and comfortably treat patients without invasive head or body frames.

The company has changed the way cancer is treated with a series of continuous system options that can track and compensate for tumor motion and eliminate the need for implanted fiducial markers.

In addition to Accuray’s commitment to the development of its cutting-edge technology, the company continues to invest in the clinical research required for oncology indications.  The evidence from more than 500 peer-reviewed publications provides the foundation of support that drives physician adoption and patient access to treatment using the CyberKnife System.

Accuray completed a successful initial public offering in February 2007 and has been ranked in the Deloitte Technology Fast 500 since 2008 as one of the fastest growing companies in North America. In 2008 the World Economic Forum named Accuray to its premier list of ‘Technology Pioneers’, acknowledging the company’sdevelopment of life-changing technology and its potential for long-term impact on business and society. In 2009, Accuray’s CEO Euan Thomson was named an ‘Entrepreneur of the Year’ by Ernst & Young in its Northern California Health and Life Sciences category. 

Accuray continues to demonstrate its leadership in the field of radiosurgery with more than 78 U.S. and foreign patents issued and more than 129 pending U.S. and foreign patent applications. The company has offices in California, Paris, Hong Kong and Tokyo with more than 450 employees worldwide

To date, the CyberKnife System has been used to treat more than 100,000 patients around the world, with more than 216 systems installed in leading hospitals throughout the Americas, Europe and Asia. CyberKnife usage continues to grow with more than 25 percent of all CyberKnife treatments occurring during the company’s fiscal year 2009 and additional clinical evidence supporting new indications being published on a continual basis.

Today, Accuray is committed not only to continuing its tradition of advancing the field of robotic radiosurgery, but also to providing its customers with the highest level of support in their ongoing efforts to fight cancer.

HISTORY

The CyberKnife System was first developed in 1987 by a team at Stanford lead by John R. Adler, M.D., a professor of neurosurgery and radiation oncology at Stanford University Medical Center. Dr. Adler had the vision todevelop a non-invasive robotic radiosurgery system with superior accuracy for treatment of tumors anywhere in the body. The revolutionary concept reached far beyond the practice of radiosurgery at the time, which restricted radiosurgery to the treatment of intracranial tumors.  In 1990, Accuray Incorporated was founded.

Accuray first received FDA clearance for the CyberKnife System in 1999 for the treatment of tumors in the head, neck and upper spine. Then in 2001, the company received FDA clearance to introduce enhancements to the CyberKnife System for the treatment of tumors anywhere in the body. 

IDB Hollandbv was founded in 1982 to promote the sale and use of radiopharmaceuticals, radio nuclides and varioussealed and unsealed sources for the use in Nuclear Medicine Departments, Industry and Research Laboratories.

IDB Hollandbv has the expertise and know-how that comes from over 28 years of experience of sales and shipping of radioactive sources and radiopharmaceuticals to customers around the world.

We continue to add new products such as Lutetium-177 and Yttrium-90 to our product line. This leads to an expansion on the international markets.

IDB Hollandbv  manufactures also custom made products for Industry, Research Laboratories and Nuclear Medicine Departments.

Our research and development program continues to generate a pipeline of new Nuclear Medicine products such as Germanium-68 / Gallium-68 generators and sources for PET cameras such as Germanium-68 sources.

COMPANY DESCRIPTION

Accuray Incorporated has acquired TomoTherapy Incorporated. The combination creates the premier radiation oncology company, offering best-in-class technologies to fight cancer. The company develops, manufactures and sells personalized, best-in-class treatment solutions that revolve around the patient. Accuray's game-changing technologies – the CyberKnife Systems and TomoTherapy Systems – set the standard of care with the aim of helping patients live longer, better lives.

Accuray's gold standard radiosurgery products and TomoTherapy's innovative radiation therapy technology are highly complementary, and both put the emphasis on patient-focused care. They serve distinct patient populations that are treated by the same medical specialty. Accuray offerings include advanced, personalized technologies for the treatment of cancer and other diseases, ranging from high-precision radiosurgery for early-stage and localized disease to image-guided, intensity-modulated radiation therapy for more advanced disease sites throughout the body. To date, more than 200,000 patients worldwide have been treated using the company’s technologies and more than 550 systems have been installed in leading hospitals around the world.

The TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. Our suite of products include the Hi·Art® treatment system, the TomoHD™ treatment system and the TomoMobile™ relocatable radiation therapy solution.

The CyberKnife® Robotic Radiosurgery System is a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney. The treatment – which delivers beams of high dose radiation to tumors with extreme accuracy – offers new hope to patients worldwide.

EVENTS

To discover more about TomoTherapy, visit us at various upcoming tradeshows and events on   www.accuray.com

  INTERNATIONAL CONFERENCE ON TOMOTHERAPY 2011 (ICT 2011)

In the past years Tomotherapy technology has moved the borders of radiation therapy, opened new treatment options and initiated the development of a new era of rotational therapy. Tomotherapy has emerged from a unique technical approach to a widely spread clinical IG-IMRT solution all over the globe.

The Heidelberg University is organizing the 2011 International Conference on Tomotherapy (ICT 2011)
in Heidelberg on September 16th and 17th, to provide a forum for those who are
interested in this technology, to discuss and learn about the clinical capabilities,
innovative concepts and ongoing clinical trials.

As the seat of Germany’s oldest University and world famous research centres
for cancer and microbiology, Heidelberg offers an excellent scientific exchange
platform with the perfect atmosphere for a successful conference.

CONFERENCE TOPICS:

Tomotherapy for tumors of
• Central nervous system
• Head & Neck
• Breast
• Gastro Intestinal
• Prostate
• Lung
• Hematooncology
• Children

Approaches for
• Radiosurgery & Hypofractionation
• Adaptive RT

Physics and Technology
• Dosimetry
• Treatment Planning
• QA
• New Technical Developments

Keynote addresses
• Current State of IMRT - Dr Steven Webb (London, UK)
• Photons vs. Particles - Prof Dr Dr Jürgen Debus
(Heidelberg, Germany)

For the full program, more information and registration, please visit the conference website: www.tomoconference2011.com  

C. Curie focuses on the radiotherapy, radiology market and molecular imaging

We ensure the supply and maintenance of products, but we also aim to promote the faster development of new applications through the creation of user groups.

We have a number of companies within our portfolio :

  provides healthcare centers with the software solutions needed to continuously improve the quality and precision of their medical imaging and radiotherapy systems.

www.aquilab.com

is part of the TeamBest™ group.  Best Medical is the manufacturer of the MOSFET dose patient monitoring systems, and the Canadian supplier of all products offered by  TeamBest ™.

www.bestmedicalcanada.com

  is recognized as a leader in the manufacturer of tissue equivalent phantoms and simulators for medical imaging, radiation therapy and procedural training.

 www.cirsinc.com

 has specialized in developing and producing systems that measures and monitors the position of the patient before and during irradiation. The systems can also be used to trigger gated treatments. The systems are compact (one unit per accelerator or CT) and easy to install and maintain. The software is modular allowing to adjust the functionality to the wishes of the user.

www.c-rad.se

  EUROMEDICAL Instruments is the sales division of EURORAD SA, one of the main Surgical Gamma Probes manufacturers in the world.

www.em-intruments.com

 is your global partner for alignment, positioning and non-contact measurement using state-of-the-art laser technology.  LAP develops, produces and distributes line lasers, laser projectors, laser sensors and systems for dimensional measurement.

www.lap-laser.com

 delivers radiation instrumentation for nuclear medicine

www.nuklear-medizintechnik.de  

  is providing the technical community in radiotherapy, diagnostic radiology and nuclear medicine with appropriate measuring and test equipment for radiation dosimetry and quality control.

www.ptw.de

 is a world leader in radiotherapy patient positioning and immobilization

www.q-fix.com               

 is a leading partner in the quality control of therapeutic radiation fields.

 www.schuster-medsys.de

    is the first company in the world to develop and offer a complete line of environmentally safe, NON-METALLIC precision skin markers to the medical industry.

 www.suremark.com

   SurgicEye provides innovative solutions for less invasive tumor surgery. Surgery is so far the only effective curative method in the treatment of several cancer types. High tech products developed, manufactured, and distributed by SurgicEye assure optimal performance during tumor surgery with increased detection rate and direct feedback of complete resection. The high quality products help surgeons focus on optimal patient outcome and increased control facilities while decreasing documentation burden.

www.surgiceye.com

 designs, produces and markets systems and solutions for those fields that use and control ionizing radiation such as hospitals, research institutes, universities and industries.

www.temasinergie.it

is a devolopment and manufacturing company for nuclear medicine accessories, QA phantoms, patient positioning- and shielding products.

www.for-med.nl

portes blindées et blocs de béton ultra lourds pour toute forme de radioprotection